Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Herpes Simplex Virus Molecular Test Receives US FDA Clearance

By LabMedica International staff writers
Posted on 02 Mar 2015
A leading developer of multiplex polymerase chain reaction technology has announced that its herpes simplex virus (HSV) types 1 and 2 assay has been granted 510 (k) market clearance. More...


The tests are based on its breakthrough technology that allows simultaneous detection and quantification of multiple targets in a single fluorescence channel, without melting curve analysis and the tests are the most comprehensive and cost-effective multiplexed polymerase chain reaction (PCR) molecular assays for infectious disease in the industry.

The US Food and Drug Administration (FDA, Silver Springs, MD, USA) has granted the market clearance for the high multiplex real-time quantitative PCR known as TOCE technology, that enables confirmation of multiple (five or more) target genetic detection and genetic variation. TOCE can implement qualitative test that analyzes multiple clinical samples and quantitative analysis bases on Cyclic Catcher Melting Temperature Analysis (cyclic-CMTA).

The company producing the approved HSV types 1 and 2 assay is Seegene (Seoul, Republic of Korea) that uses the Allplex tests which are based on its breakthrough MuDT technology. This powerful technology is capable of simultaneous quantification and detection/discrimination of multiple targets in a single channel without additional melting curve analysis after amplification step. It satisfies the growing demands for both high multiplexing and quantification in a single assay by overcoming the current technology barrier of “one channel, only one cycle threshold (Ct).” MuDT technology opens a new chapter of PCR-based molecular diagnostics to deliver a more comprehensive and actionable diagnostic information.

Jong-Yoon Chun, PhD, founder, CTO and CEO of Seegene, said, “This is an important milestone in support of our planned entry into the USA, the largest molecular diagnostic market in the world. After more than 10 years of extensive efforts to continually develop and commercialize novel technologies to surpass the capabilities of real-time PCR, we successfully invented MuDT technology, an ultimate multiplex real-time PCR technology that marks a new era in the molecular diagnostics industry. Through the US FDA approval, Seegene now intends to actively enhance its leadership in the multiplex real-time PCR diagnostic testing market.”

Related Links:
US Food and Drug Administration 
Seegene 



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.